RON is not a prognostic marker for resectable pancreatic cancer

Tactacan, C. M. et al. (2012) RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer, 12(1), 395. (doi: 10.1186/1471-2407-12-395) (PMID:22958871) (PMCID:PMC3532183)

Abstract

Background: The receptor tyrosine kinase RON exhibits increased expression during pancreatic cancer progression and promotes migration, invasion and gemcitabine resistance of pancreatic cancer cells in experimental models. However, the prognostic significance of RON expression in pancreatic cancer is unknown. Methods: RON expression was characterized in several large cohorts, including a prospective study, totaling 492 pancreatic cancer patients and relationships with patient outcome and clinico-pathologic variables were assessed. Results: RON expression was associated with outcome in a training set, but this was not recapitulated in the validation set, nor was there any association with therapeutic responsiveness in the validation set or the prospective study. Conclusions: Although RON is implicated in pancreatic cancer progression in experimental models, and may constitute a therapeutic target, RON expression is not associated with prognosis or therapeutic responsiveness in resected pancreatic cancer.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Biankin, Professor Andrew and Grimmond, Professor Sean and Chang, Professor David
• Authors: Tactacan, C. M., Chang, D. K., Cowley, M. J., Humphrey, E. s., Wu, J., Gill, A. J., Chou, A., Nones, K., Grimmond, S. M., Sutherland, R. L., Biankin, A. V., and Daly, R. J.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: BMC Cancer
• Publisher: BioMed Central Ltd.
• ISSN: 1471-2407
• ISSN (Online): 1471-2407
• Copyright Holders: Copyright © 2012 Tactacan et al.
• First Published: First published in BMC Cancer 12(1):395
• Publisher Policy: Reproduced under a Creative Commons License